224 related articles for article (PubMed ID: 37545503)
1. Anti-interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study.
Wang SH; Shan Y; Li SZ; Zuo YG
Front Immunol; 2023; 14():1165106. PubMed ID: 37545503
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Dupilumab in Patients With Bullous Pemphigoid.
Zhao L; Wang Q; Liang G; Zhou Y; Yiu N; Yang B; Zhang G; Li W; Feng S; Shang P; Chen X; Zhu X; Zheng J; Pan M; Wang M
JAMA Dermatol; 2023 Sep; 159(9):953-960. PubMed ID: 37531116
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study.
Huang D; Zhang Y; Yu Y; Jiang Y; Kong L; Ding Y; Shi Y; Gao Y
Int Immunopharmacol; 2023 Dec; 125(Pt A):111157. PubMed ID: 37925949
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab for bullous pemphigoid with intractable pruritus.
Seidman JS; Eichenfield DZ; Orme CM
Dermatol Online J; 2019 Nov; 25(11):. PubMed ID: 32045153
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series.
Abdat R; Waldman RA; de Bedout V; Czernik A; Mcleod M; King B; Gordon S; Ahmed R; Nichols A; Rothe M; Rosmarin D
J Am Acad Dermatol; 2020 Jul; 83(1):46-52. PubMed ID: 32179082
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.
Zhang Y; Xu Q; Chen L; Chen J; Zhang J; Zou Y; Gong T; Ji C
Front Immunol; 2021; 12():738907. PubMed ID: 34721404
[TBL] [Abstract][Full Text] [Related]
7. Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.
Alexandre M; Bohelay G; Gille T; Le Roux-Villet C; Soued I; Morin F; Caux F; Grootenboer-Mignot S; Prost-Squarcioni C
Front Immunol; 2022; 13():874108. PubMed ID: 35514989
[TBL] [Abstract][Full Text] [Related]
8. Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study.
Hu L; Huang R; Jiang F; You S; Wu Q
Immun Inflamm Dis; 2023 Jul; 11(7):e924. PubMed ID: 37506153
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Bullous Pemphigoid With Dupilumab: A Case Series of 30 Patients.
Miller AC; Temiz LA; Adjei S; Duran MA; Sassmannshausen J; Dominguez A; Thomas C; Schmidt JD; Bernhardt M; Doolittle-Amieva CJ; Moshiri AS; Thompson AJ; Pyoung Kim-Lim P; Mattia AV; Tyring SK
J Drugs Dermatol; 2024 Jun; 23(6):e144-e148. PubMed ID: 38834228
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature.
Saleh M; Reedy M; Torok H; Weaver J
Dermatol Online J; 2021 Apr; 27(4):. PubMed ID: 33999579
[TBL] [Abstract][Full Text] [Related]
11. Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT.
Murrell DF; Joly P; Werth VP; Ujiie H; Worm M; Mangold AR; Avetisova E; Maloney J; Laws E; Mortensen E; Dubost-Brama A; Shabbir A
Adv Ther; 2024 Mar; ():. PubMed ID: 38443648
[TBL] [Abstract][Full Text] [Related]
12. Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid.
Chen F; Wang Y; Chen X; Yang N; Li L
Ann Med; 2023 Dec; 55(1):1156-1170. PubMed ID: 36999962
[No Abstract] [Full Text] [Related]
13. Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update.
Karakioulaki M; Eyerich K; Patsatsi A
Am J Clin Dermatol; 2024 Mar; 25(2):195-212. PubMed ID: 38157140
[TBL] [Abstract][Full Text] [Related]
14. Case report: Dupilumab for the treatment of bullous pemphigoid.
Wang M; Wang J; Shi B
Dermatol Ther; 2022 Jul; 35(7):e15541. PubMed ID: 35478478
[TBL] [Abstract][Full Text] [Related]
15. Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primarily suppressing T-helper 2 cytokines.
Takamura S; Teraki Y
J Dermatol; 2022 Sep; 49(9):845-850. PubMed ID: 35538742
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.
Seyed Jafari SM; Feldmeyer L; Bossart S; Simon D; Schlapbach C; Borradori L
Front Immunol; 2020; 11():611549. PubMed ID: 33584689
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid.
Yang J; Gao H; Zhang Z; Tang C; Chen Z; Wang L; Yang F; Chen S; He S; Liu S; Tang L; Xu Y; Hu Y; Ma L; Zhao Y; Luo X
Dermatol Ther; 2022 Aug; 35(8):e15648. PubMed ID: 35715972
[TBL] [Abstract][Full Text] [Related]
18. Nine cases of refractory bullous pemphigoid treated with dupilumab and literature review.
Liang J; Abulikemu K; Maolidan ; Hu F; Zhao J; Qiu Y; Wang Q; Sang Y; Hong Y; Kang X
Int Immunopharmacol; 2023 Mar; 116():109788. PubMed ID: 36731156
[TBL] [Abstract][Full Text] [Related]
19. Non-Bullous Pemphigoid: A Single-Center Retrospective Study.
Moar A; Azzolini A; Tessari G; Schena D; Girolomoni G
Dermatology; 2021; 237(6):1039-1045. PubMed ID: 33979792
[TBL] [Abstract][Full Text] [Related]
20. Association of bullous pemphigoid and comorbid health conditions: a case-control study.
Lee S; Rastogi S; Hsu DY; Nardone B; Silverberg JI
Arch Dermatol Res; 2021 Jul; 313(5):327-332. PubMed ID: 32647978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
